CoChat

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

AIMS/HYPOTHESIS: Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new basal insulin with an ultra-long flat action profile. The acute physiological responses to hypoglycaemia with IDeg and insulin glargine (A21Gly,B31Arg,B32Arg human insulin; IGlar) were compared. METHODS: Twenty-eight adult type 1 diabetic patients with normal hypoglycaemia awareness (age = 41 ± 12 years, HbA1c = 7.8 ± 0.6% [62.8 ± 7 mmol/mol]) were randomised to once-daily IDeg or IGlar for 5 days in a two-period crossover design. Participants and research staff were blinded to group assignment. Patients were assigned the lowest available randomisation number from a set of blinded randomisation codes provided by the trial sponsor. Hypoglycaemia was induced by administering three times the usual daily insulin dose at midnight on day 5. Plasma glucose (PG) was stabilised by glucose clamp (5.5 mmol/l) for 7-9 h post dosing. Next morning, PG was allowed to decrease stepwise from 5.5 to 3.5 mmol/l (maintained for 30 min) to 2.5 mmol/l (for 15 min). PG was then increased to 3.9 mmol/l (for 120 min), before being returned to baseline. Hypoglycaemic symptom score (HSS), hypoglycaemic awareness, cognitive function, counter-regulatory hormones and vital signs were assessed during each glucose plateau. The primary analysis was to compare IDeg vs IGlar with respect to HSS at nadir PG concentration (2.5 mmol/l). RESULTS: The full analysis set for treatment comparisons comprised data from all 28 exposed patients. Rates of PG decline and PG at nadir were similar for IDeg and IGlar. No treatment differences in HSS (estimated difference: 0.17 [95% CI -1.71, 2.05]; p > 0.05), cognitive function or awareness were observed at any time. Growth hormone and cortisol responses during hypoglycaemia were greater with IDeg than IGlar (AUC treatment ratio [IDeg/IGlar]: 2.44 [1.30, 4.60], p < 0.01; and 1.23 [1.01, 1.50]; p < 0.05), and adrenaline (epinephrine) responses trended higher (1.40 [0.96, 2.04], p = 0.07). The rates of recovery from hypoglycaemia were similar. CONCLUSIONS/INTERPRETATION: IDeg and IGlar elicit comparable symptomatic and cognitive responses to induced hypoglycaemia. IDeg may elicit a moderately greater endocrine response, but times to PG recovery were similar for the two insulins. TRIAL REGISTRATION: ClinicalTrials.gov NCT01002768. FUNDING: Novo Nordisk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-013-3056-0

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Stepwise glucose clamp procedure. Run in: participants were clamped at a PG level of 5.5 mmol/l (100 mg/dl) 2 h before dosing until 7–9 h after dosing. Hypoglycaemia induction: variable i.v. glucose was terminated and PG was allowed to decrease to 3.5 mmol/l (63 mg/dl), maintained for 30 min, and thereafter to a target nadir of 2.5 mmol/l (45 mg/dl), maintained for 15 min. Recovery: at end of nadir PG, a fixed i.v. glucose infusion (5.5 mg kg−1 min−1) was initiated, and PG was allowed to increase to 3.9 mmol/l (70 mg/dl), maintained for 120 min, and thereafter to 5.5 mmol/l (100 mg/dl). Thick broken line, variable glucose infusion rate (GIR); thick unbroken line, fixed i.v. glucose infusion (5.5 mg kg−1 min−1)
Fig. 1 Stepwise glucose clamp procedure. Run in: participants were clamped at a PG level of 5.5 mmol/l (100 mg/dl) 2 h before dosing until 7–9 h after dosing. Hypoglycaemia induction: variable i.v. glucose was terminated and PG was allowed to decrease to 3.5 mmol/l (63 mg/dl), maintained for 30 min, and thereafter to a target nadir of 2.5 mmol/l (45 mg/dl), maintained for 15 min. Recovery: at end of nadir PG, a fixed i.v. glucose infusion (5.5 mg kg−1 min−1) was initiated, and PG was allowed to increase to 3.9 mmol/l (70 mg/dl), maintained for 120 min, and thereafter to 5.5 mmol/l (100 mg/dl). Thick broken line, variable glucose infusion rate (GIR); thick unbroken line, fixed i.v. glucose infusion (5.5 mg kg−1 min−1)CC BY-NC · PubMed Central
Fig. 2 Flow of participants through the trial. FAS, full analysis set
Fig. 2 Flow of participants through the trial. FAS, full analysis setCC BY-NC · PubMed Central
Fig. 3 Mean time to PG targets (a) and mean glucose infusion rate (b) during development of, and recovery from, hypoglycaemia. In (a), time point zero has been defined as when PG = 4.5 mmol/l, because a decline in PG below 4.5 mmol/l is considered to be the threshold for hypoglycaemic response. Black circles, IDeg; white squares, IGlar. In (b), *denotes statistically significant estimated treatment difference in rate of glucose infusion (p < 0.05). Grey bars, IDeg; white bars, IGlar; narrow vertical black bars, 95% CI. GIR, glucose infusion rate
Fig. 3 Mean time to PG targets (a) and mean glucose infusion rate (b) during development of, and recovery from, hypoglycaemia. In (a), time point zero has been defined as when PG = 4.5 mmol/l, because a decline in PG below 4.5 mmol/l is considered to be the threshold for hypoglycaemic response. Black circles, IDeg; white squares, IGlar. In (b), *denotes statistically significant estimated treatment difference in rate of glucose infusion (p < 0.05). Grey bars, IDeg; white bars, IGlar; narrow vertical black bars, 95% CI. GIR, glucose infusion rateCC BY-NC · PubMed Central
Fig. 4 Baseline-adjusted HSS during development of, and recovery from, hypoglycaemia. Black circles, IDeg; white squares, IGlar; vertical bars, SEM
Fig. 4 Baseline-adjusted HSS during development of, and recovery from, hypoglycaemia. Black circles, IDeg; white squares, IGlar; vertical bars, SEMCC BY-NC · PubMed Central
Fig. 5 Baseline-adjusted cognitive function performance test scores during development of, and recovery from, hypoglycaemia for (a) trail making B, (b) digit symbol substitution test (DSST), (c) four-choice reaction time (percentage correct answers) and (d) four-choice reaction time (response time). Black circles, IDeg; white squares, IGlar; vertical bars, SEM. *denotes statistically significant estimated treatment difference in slopes (p < 0.05). TMB, trail making B; 4CRT, four-choice reaction time
Fig. 5 Baseline-adjusted cognitive function performance test scores during development of, and recovery from, hypoglycaemia for (a) trail making B, (b) digit symbol substitution test (DSST), (c) four-choice reaction time (percentage correct answers) and (d) four-choice reaction time (response time). Black circles, IDeg; white squares, IGlar; vertical bars, SEM. *denotes statistically significant estimated treatment difference in slopes (p < 0.05). TMB, trail making B; 4CRT, four-choice reaction timeCC BY-NC · PubMed Central
Fig. 6 Counter-regulatory hormone response during development of, and recovery from, hypoglycaemia for (a) growth hormone, (b) cortisol, (c) adrenaline, (d) noradrenaline and (e) glucagon. Black circles, IDeg; white squares, IGlar; vertical bars, SEM. *denotes statistically significant estimated treatment difference in slopes (p < 0.05)
Fig. 6 Counter-regulatory hormone response during development of, and recovery from, hypoglycaemia for (a) growth hormone, (b) cortisol, (c) adrenaline, (d) noradrenaline and (e) glucagon. Black circles, IDeg; white squares, IGlar; vertical bars, SEM. *denotes statistically significant estimated treatment difference in slopes (p < 0.05)CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 29

Metadata

Authors
Koehler, G., Heller, S., Korsatko, S., Roepstorff, C., Rasmussen, S., Haahr, H., & Pieber, T. R.
Affiliations
  • University of Graz (AT)
  • University of Sheffield (GB)
  • Novo Nordisk (Denmark) (DK)
Corresponding author
Pieber, Thomas R.
Venue
Diabetologia
Published
2013-09-22
Volume
57
Issue
1
Pages
40-49
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2097913137
Cited by
29
References
38
Citations by year
2026: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 6 · 2015: 7 · 2014: 5
FWCI
4.73
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • MannKind Corporation
  • National Institute for Health and Care Research (NF-SI-0611-10248)
  • Novo Nordisk
  • Karl-Franzens-Universität Graz
  • Medizinische Universität Graz
  • Servier
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
insulin degludec, insulin glargine, type 1 diabetes, hypoglycemia, growth hormone, cortisol, cognitive function, basal insulin, glucose clamp, insulin pharmacokinetics, insulin pharmacodynamics
MeSH terms
Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Hypoglycemia, Male, Middle Aged, Cross-Over Studies, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. https://app.cochat.ai/papers/10.1007/s00125-013-3056-0
The paper
Koehler, G., Heller, S., Korsatko, S., Roepstorff, C., Rasmussen, S., Haahr, H., & Pieber, T. R. (2014). Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia. https://doi.org/10.1007/s00125-013-3056-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.